Herm Rosenman
CIK 1230057 · Chief Financial Officer · last filed 2026-06-26
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
NTRA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
94C INNOVATION DRIVE, HILTON PARK
SAN DIEGO, X0 OX14 4RZ
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NTRA | Director | 4,250 | $393.44 | $1.67M | -$28.40M | 48 | 2026-06-26 |
| DermTech, Inc. (DMTK) Delisted | Director | 134,576 | $0.09 | $12.7K | $274.6K | 8 | 2023-06-05 |
| Oxford Immunotec Global PLC (OXFD) Delisted | Director | 4,081 | — | — | $0 | 7 | 2020-06-26 |
| VIVUS INC (VVUS) Delisted | Director | 36,168 | — | — | $159.0K | 21 | 2020-02-24 |
| GPRO | Senior VP, Finance & CFO | 0 | $1.05 | $0 | -$3.25M | 17 | 2012-08-02 |
| ARYx Therapeutics, Inc. (ARYX) Delisted | Director | — | — | — | $0 | 3 | 2010-05-03 |
| INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Director | — | $0.04 | — | $0 | 1 | 2007-09-14 |
Recent Filings · Page 4 of 11
109 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-05-27 | NTRA | Exer (M) | +1,307 | $0 | EDGAR |
| 2022-05-11 | DermTech, Inc. (DMTK) Delisted | Buy (P) | +20,000 | $137.3K | EDGAR |
| 2021-11-09 | NTRA | Mixed | — | -$5.11M | EDGAR |
| 2021-11-09 | NTRA | Mixed | — | -$1.19M | EDGAR |
| 2021-06-02 | NTRA | Mixed | +2,856 | $0 | EDGAR |
| 2021-05-28 | DermTech, Inc. (DMTK) Delisted | Grant (A) | +9,158 | $0 | EDGAR |
| 2021-03-12 | — | Disp (D) | −4,081 | -$89.8K | |
| 2020-06-26 | Oxford Immunotec Global PLC (OXFD) Delisted | Grant (A) | +4,081 | $0 | EDGAR |
| 2020-06-19 | DermTech, Inc. (DMTK) Delisted | Grant (A) | +8,000 | $0 | EDGAR |
| 2020-06-16 | NTRA | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.